Q4 2018 13F Holders as of 31 Dec 2018
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
119,650,114
-
Share change
-
-6,230,815
-
Total reported value
-
$346,952,317
-
Put/Call ratio
-
60%
-
Price per share
-
$2.90
-
Number of holders
-
144
-
Value change
-
-$17,349,555
-
Number of buys
-
48
-
Number of sells
-
80
Institutional Holders of PDL BIOPHARMA INC COM - COM (Y104L) as of Q4 2018
As of 31 Dec 2018,
PDL BIOPHARMA INC COM - COM (Y104L) was held by
144 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
119,650,114 shares.
The largest 10 holders included
BlackRock Inc., DIMENSIONAL FUND ADVISORS LP, Vanguard Group Inc, RENAISSANCE TECHNOLOGIES LLC, KENNEDY CAPITAL MANAGEMENT, INC., STATE STREET CORP, Connor, Clark & Lunn Investment Management Ltd., NORTHERN TRUST CORP, BRANDES INVESTMENT PARTNERS, LP, and CITADEL ADVISORS LLC.
This page lists
144
institutional shareholders reporting positions in this security
for the Q4 2018 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.